Drugmaker Announces , Promising Results of Potential , Alzheimer's Treatment.
On September 28, shares of Biogen and other drugmakers
researching Alzheimer's disease skyrocketed after Japan's
Eisai Co. announced promising late-stage study results.
'Time' reports that the company
said its potential treatment appeared
to slow the progress of the fatal disease.
On September 27, Eisai announced
the results of a global study of nearly
1,800 people with early-stage Alzheimer's.
According to the drugmaker, early results
show that the treatment reduced
patients' decline by 27% over 18 months.
Eisai Co. also announced plans
to discuss the trial's full results
at a conference in November.
'Time' reports that the company plans to publish
the findings in a peer-reviewed medical journal.
Meanwhile, the company has already sought
accelerated approval from the
U.S. Food and Drug Administration.
'Time' reports that the regulatory agency is expected to make a decision by early 2023.
The Alzheimer's Association released
a statement calling the study's findings the most
encouraging to date for potential treatments.
Following the announcement,
shares of Biogen Inc. jumped over 50%
in premarket trading to top $300